Immuron Pivots to Partnerships, Fueling Growth and Clinical Pipeline

MELBOURNE, Australia – February 25, 2026 – Australian biopharmaceutical firm Immuron Limited has announced a strategic reset designed to accelerate its high-value clinical programs, signaling a pivotal maturation from a development-stage entity to a commercially growing company with a de-risked path forward. The announcement coincided with the release of strong half-year financial results, showing consistent revenue growth and significant market traction in the United States.

Immuron reported global sales of AUD$4.2 million for the first half of fiscal year 2026, underpinned by robust performance of its flagship product, Travelan®, for traveler's diarrhea. This financial stability, bolstered by a cash position of AUD$10.0 million, provides a firm foundation for its new partnership-focused strategy. The company is now actively seeking collaborations to fund the expensive late-stage clinical development of its key assets: a new indication for Travelan® (IMM-124E) and a novel treatment for Clostridioides difficile infection (IMM-529).

Commercial Momentum Builds

Immuron's transition is backed by tangible commercial success. The company's H1 FY26 sales represent a 5% increase over the prior comparative period, demonstrating a steady upward trajectory. Growth was particularly strong in its home market of Australia, where Travelan® sales climbed 13% to AUD$3.3 million. This increase is attributed to a multi-pronged strategy including extensive digital marketing campaigns, expanded retail presence in major pharmacy groups, and a general rebound in international travel.

Crucially, the U.S. market has emerged as a powerful growth engine, with sales surging 17% year-over-year to AUD$0.9 million. This momentum is driven by a revamped Amazon.com storefront and targeted social media marketing efforts, indicating a successful digital-first approach to one of the world's largest consumer health markets. While sales in Canada experienced an earlier dip, they have shown a dramatic recovery in the second quarter, jumping 191% quarter-on-quarter following new retail listings and promotions.

Further diversifying its revenue stream, Immuron has also begun to see early results from its distribution of ProIBS®, a certified medical device for treating symptoms of Irritable Bowel Syndrome. The product is now stocked by major Australian pharmacy wholesalers, tapping into a domestic market for digestive remedies estimated to be worth over AU$221 million.

A Strategic Shift to De-Risk and Accelerate

The centerpiece of Immuron's announcement is its strategic decision to pursue partnerships to advance its clinical pipeline. This move reflects a sophisticated understanding of the biopharmaceutical landscape, where the costs of late-stage clinical trials can be prohibitive for smaller companies. Phase 3 trials, the final hurdle before seeking regulatory approval, frequently cost between $20 million and $100 million, and sometimes far more.

By adopting an asset-light, partnership-driven model, Immuron aims to mitigate this substantial financial risk. Such collaborations typically involve a larger pharmaceutical partner providing funding—often in the form of upfront payments, milestone-based payments, and future royalties—in exchange for rights to develop and commercialize the drug. This approach provides Immuron with non-dilutive capital, preserving shareholder value while leveraging the partner's extensive experience in navigating complex regulatory pathways, large-scale manufacturing, and global commercialization.

This strategy allows Immuron to focus on its core competency: leveraging its proprietary 'Hyper-Immune' platform to discover and develop novel polyclonal antibody therapies. A successful partnership not only validates the technology in the eyes of the market but can also significantly accelerate the timeline to get potentially life-changing treatments to patients.

Key Clinical Programs Reach FDA Milestones

Immuron's attractiveness to potential partners is significantly enhanced by recent progress in its two lead clinical programs, both of which have reached critical milestones with the U.S. Food and Drug Administration (FDA).

First, IMM-124E, the active pharmaceutical ingredient in Travelan®, is now eligible for an End-of-Phase-2 (EOP2) meeting with the FDA. This formal meeting is a crucial step to align with the agency on the design of a Phase 3 trial, which would aim to get IMM-124E approved as a prescription drug for the prevention of traveler's diarrhea. While Travelan® is currently sold as a dietary supplement in the U.S., full FDA drug approval would unlock a much larger market, with some forecasts projecting potential peak annual sales exceeding USD$100 million.

Second, the company's Investigational New Drug (IND) application for IMM-529 has been approved by the FDA. This approval gives Immuron the green light to begin human clinical trials in the U.S. for its promising treatment targeting Clostridioides difficile infection (CDI). The company plans to initiate a Phase 2 randomized, placebo-controlled study in Australia in the first half of 2026, which will evaluate the safety and efficacy of IMM-529 as an adjunctive therapy alongside standard-of-care antibiotics.

Targeting a Major Public Health Threat

The advancement of IMM-529 is particularly significant, as it targets a major unmet medical need. C. difficile is a bacterium that causes severe diarrhea and colitis, leading to nearly half a million infections and an estimated 29,000 deaths in the U.S. each year. A primary challenge in treating CDI is its high rate of recurrence, which affects about 20% of patients after initial treatment and can nearly triple associated healthcare costs.

Immuron's IMM-529 offers a novel approach. Unlike broad-spectrum antibiotics that can disrupt the natural gut flora and sometimes contribute to recurrence, IMM-529 is a highly targeted polyclonal antibody therapy. It is designed to work with standard antibiotics, employing a unique triple-action mechanism that neutralizes the primary virulence factor (Toxin B) while also targeting the bacterial spores and vegetative cells. This helps clear the infection and prevent relapse without causing further damage to the patient's microbiome.

Pre-clinical studies have been highly promising, showing IMM-529 was effective in preventing primary disease, protecting against recurrence, and treating active disease. Independent market analysis suggests that, if proven effective in human trials, IMM-529 could be positioned early in the treatment algorithm for both first-episode and recurrent CDI, potentially capturing a market with yearly revenues estimated at US$400 million. This positions the asset as a high-value candidate for a major pharmaceutical partnership.